Media Partners

voicelogo (002)

PharmaVOICE

PharmaVOICE magazine reaches more than 46,000 BPA qualified subscribers and 60,000 users with its digital edition. PharmaVOICE is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including Social Media, WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts.

Cell & Gene - Media Partner

Cell & Gene 

Cell & Gene provides actionable information to professionals involved in the development and commercialization of cell and gene therapies. Through the original editorial published on the site, Cell & Gene facilitates the sharing of insights on challenges, trends, and best practices in this burgeoning field. Cell & Gene’s editorial scope spans the entire product lifecycle from basic research to commercialization.

Gene Therapy Net - Media Partner

Gene Therapy Net

Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.

pharmaphorum - media partner

pharmaphorum

pharmaphorum uses content to connect the pharmaceutical industry and other innovators to advance healthcare, leveraging its own global publications and delivering direct content marketing, medical and communications services to clients in the healthcare sector. pharmaphorum.com, and its associated digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate.